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Objectives: Review of the primary results and secondary analyses from the European Carotid Surgery Trial (ECST) and
the North American Symptomatic Carotid Endarterectomy Trial (NASCET).
Design: Review of 48 ECST and NASCET papers.
Results: The simple assumption that all patients with a symptomatic stenosis 470% benefit from CEA is untenable.
Approximately 70±75% will not have a stroke if treated medically. The ECST and NASCET have identified subgroups that
should have expedited investigation and surgery (male sex, age 475 years, 90±99% stenosis, irregular plaque, hemispheric
symptoms, recurrent events for 46 months, contralateral occlusion, multiple co-morbidity). Accordingly development of
local protocols for patient selection/exclusion should involve surgeons and physicians and take account of the local operative
risk. The ECST and NASCET have also shown that the ubiquitous `` string sign'' is not associated with a high risk of stroke,
and emergency CEA is unnecessary.
Conclusions: Surgeons must quote their own results and be aware that a high operative risk reduces long-term benefit.
Accordingly, in those centres with a higher operative death/stroke rate, some `` lower risk'' patients should probably be
considered for best medical therapy alone. It is hoped that pooling of the ECST and NASCET databases will enable more
definitive guidelines to be developed regarding who benefits most from CEA.
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Introduction
Within three decades of its introduction, carotid endar-
terectomy (CEA) became the most commonly per-
formed arterial procedure in the world. However,
concerns about case selection and effectiveness1,2 led
to a reduction in the number of operations performed
world-wide and became a catalyst for the European
Carotid Surgery Trial (ECST) and the North American
Symptomatic Carotid Endarterectomy Trial (NASCET).
ECST and NASCET published data on the benefit of
surgery for recently symptomatic severe carotid dis-
ease in 1991.3,4 The ECST also showed that surgery
was harmful in patients with only mild stenosis.3 The
role of surgery for moderate stenosis was clarified
later.5,6 For many, this signalled an end to the debate.
However, a number of controversies remain, fuelled in
part by the emergence of angioplasty as an alternative
to endarterectomy, improvements in `` best medical
therapy'' (BMT) and questions about the generalisabil-
ity of the results of large international trials to routine
practice. Similarly confusing has been the `` drip feed''
of secondary analyses, particularly from NASCET,
which may have influenced management decisions
in a manner that was not intended. The ECST has
not published any single variable subgroup analyses,
but NASCET has published several papers reporting
single variable subgroup analyses based on small
numbers of patients and outcome events. Overall,
ECST and NASCET have now published 48 papers
(ECST 16, NASCET 32) in 12 journals over a
12-year period.3±50 Even for those interested in stroke
prevention, it can be difficult to keep abreast of the
literature. The aims of this paper are therefore two-
fold. Firstly, to summarise the principal results from
the trials. Secondly, to review the secondary analyses
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which have been reported and determine their impli-
cations for surgical practice. Both aims require the
inclusion of some previously unreported data from the
ECST. With this information, each unit can thereafter
review local practice and modify protocols for fast-
trackinvestigationand/orcaseselectionasappropriate.
Data presentation
Readers will already be aware of the potential for
confusion regarding data interpretation in ECST and
NASCET. This not only applies to methods for mea-
suring stenosis, but also to the definition of stroke,
small sub-group analyses and varying periods of
follow-up. For example, NASCET defined operative
stroke as being present if the deficit persisted for
424 h. ECST only included patients with a deficit per-
sisting beyond seven days. NASCET has always
reported the long-term ipsilateral stroke/death rate,
while ECST usually quotes the any stroke/death rate.
In this review, the ipsilateral stroke/death rate is
listed where possible. Surgical or medical risk is the
risk of ipsilateral stroke and operative stroke or death
at the specified time period. The operative risk is the
30-day death and/or any stroke rate. Absolute risk
reduction (ARR) is the difference between medical
and surgical risks. Relative risk reduction (RRR) is
the proportional reduction in stroke risk conferred
by surgery over best medical therapy. The `` number
needed to treat'' to prevent one stroke (NNT) is
obtained by dividing 100 by the ARR. The number
of strokes prevented by performing 1000 CEAs is
calculated by dividing 1000 by the NNT. The latter
parameters enable readers to gauge the `` relative''
effectiveness of CEA in different clinical situations.
The actual numbers should not be taken too literally,
and appropriate allowance should be made when
estimates are based on a small numbers of end-points.
The International Trials
Methodology
The U.K. Medical Research Council sponsored the
ECST. Between 1981±1994, 3024 patients with symp-
tomatic carotid disease were randomised to best med-
ical therapy (BMT) or CEA plus BMT. The National
Institute of Neurological Disease and Stroke funded
NASCET. Between 1987±1996, 2885 patients with ipsi-
lateral carotid symptoms were randomised. The ECST
recruited from 100 centres in 14 European countries,
the NASCET from 106 centres mainly in the U.S.A.
and Canada.
The methods of the ECST and NASCET were simi-
lar. Patients were recruited if they had had a recent
carotid distribution transient ischaemic attack, non-
disabling ischaemic stroke, or a retinal infarction,
and had a stenosis of the ipsilateral (symptomatic)
carotid artery. Each trial required that patients were
seen by a neurologist or a stroke physician prior to
randomisation to confirm their eligibility. Each trial
also required that the symptomatic carotid artery
(and preferably the contralateral carotid artery and
intracranial circulation) was imaged using angiog-
raphy (ideally selective catheter angiography).
However, strokes or deaths due to pre-randomisation
angiography were not recorded and were not
included in the analysis in those cases that were
subsequently randomised. Degree of stenosis of
the symptomatic internal carotid artery (ICA) was
quantified centrally, although randomisation was
made on the basis of each centre's interpretation of
disease severity. In both trials, treatment was allocated
by central telephone randomisation stratified by cen-
tre. Surgeons were only permitted to randomise
patients following review of their recent `` track
record''. CEA was performed as soon as possible
after randomisation. The peri-operative period
extended from the date of randomisation until 30
days after surgery. Follow-up was performed at set
intervals by a neurologist or a stroke physician. The
main differences in methods between the trials were
as follows:
(1) Patients with any degree of carotid stenosis could
be randomised in the ECST, whereas the NASCET
aimed to include only patients with 430% ste-
noses. Analyses of the effect of treatment were
pre-specified according to severity of stenosis as
mild (0±29%), moderate (30±69%) or severe
(70±99%) in the ECST, and as moderate (30±69%)
or severe (70±99%) in NASCET.
(2) Time from last symptoms to randomisation had to
be less than 4 months in the NASCET (changed to
6 months after 1991) and less than 6 months in
the ECST.
(3) There was a difference between ECSTand NASCET
in the manner of selection and exclusion from the
trials. In the ECST, inclusion and exclusion were
based on the `` uncertainty principle'' (i.e. if both
the patient and clinicians were uncertain about
whether or not to recommend surgery then the
patient was eligible), whereas the NASCET had
more strictly specified eligibility criteria.19
(4) Patients were randomised in a 50:50 ratio in the
NASCET, and in a 60 (surgery):40 (no surgery)
ratio in the ECST.
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(5) The recommended dose of aspirin was 1300 mg in
the NASCET, and unspecified in the ECST.
(6) Follow-up was performed at 1, 3, 6, 9 and
12 months, and 4 monthly thereafter in the
NASCET, and at 4 and 12 months and annually
thereafter in the ECST.
(7) In the ECST, a follow-up stroke was defined as a
focal neurological deficit lasting 47 days, but did
not include retinal ischaemic events. In NASCET,
stroke was defined as any neurological or retinal
ischaemic deficit persisting beyond 24 h. In both
trials, stroke severity was scored following neuro-
logical assessment at 6 months using the modified
Rankin classification.51
Measurement of stenosis
Both trials used the minimum residual luminal diam-
eter as the numerator in the calculation of the degree of
carotid stenosis. In ECST, the denominator was the
estimated artery diameter at the same point, usually
the carotid bulb (Fig. 1). In NASCET, the denominator
was the diameter of a disease free point in the ICA
above the stenosis where the walls of the vessel are
parallel. These different methods produce different
values for the same `` stenosis''. For example, a NASCET
60% stenosis is roughly equivalent to an ECST 80%
stenosis.8 Neither trial used the common carotid (CCA)
method in which the denominator is the diameter of
common carotid artery proximal to the bifurcation.8
The different methods of measuring the degree of
stenosis are each of similar predictive value for stroke
risk on medical treatment, but the CCA method is
slightly more reproducible than the others.7 ECST
observed that the relationship between the stenosis
measurements derived from the different methods
were almost linear, thus enabling conversion from
one to another.8 ECST concluded that the CCA method
was preferable for use in future trials. NASCET found
that the relationship was non-linear at very mild
degrees of stenosis, and did not support the use of
the CCA method.27 ECST also studied the reproduci-
bility of measurement of stenosis according to the
technique of angiography.11 Inter-observer agreement
was good for division into mild, moderate or severe
disease using selective angiography ( 0.68) and arch
angiography ( 0.64), but was poor for intravenous
DSA ( 0.29).
Principal Results from ECST & NASCET
Late ipsilateral stroke/death
Both trials observed significant benefit for CEA in
patients with 70±99% stenoses (Table 1). ECST found
no evidence of benefit for CEA in patients with mild
disease. NASCET showed that patients with 50±69%
stenoses gained a small but significant benefit from
CEA. This group is equivalent to those patients with
70±79% stenoses in the ECST.12 In NASCET patients
with 50±69% stenoses, CEA conferred maximal benefit
in (i) males, (ii) patients presenting with stroke and
(iii) those with hemispheric as opposed to retinal
Fig. 1. ECST and NASCET methods for measuring stenosis. Repro-
duced by permission of The Lancet.65
Table 1. Long term risk of ipsilateral stroke (including peri-operative stroke or death).
Stenosis (%) Surgical risk (%) Medical risk (%) ARR (%) RRR (%) NNT Strokes prevented
per 1000 CEAs
ECST
530 9.8 at 5 years 3.9 at 5 years ÿ5.9 n/a n/a n/a
30±49 10.2 at 5 years 8.2 at 5 years ÿ2.0 n/a n/a n/a
50±69 15.0 at 5 years 12.1 at 5 years ÿ2.9 n/a n/a n/a
70±99 10.5 at 5 years 19.0 at 5 years 8.5 45 12 83 at 5 years
NASCET
30±49 14.9 at 5 years 18.7 at 5 years 3.8 20 26 38 at 5 years
50±69 15.7 at 3 years 22.2 at 3 years 6.5 29 15 67 at 3 years
70±99 8.9 at 3 years 28.3 at 3 years 19.4 69 5 200 at 3 years
ARR absolute risk reduction, RRR relative risk reduction, NNTnumber of CEAs to prevent one ipsilateral stroke, n/anot applicable.
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symptoms.6 Twelve CEAs in male patients with
50±69% stenoses were required to prevent one
ipsilateral stroke compared with 67 in women and 16
CEAs were required to prevent one disabling stroke in
men as compared with 125 in women.6
Operative risk
The 30-day risk of death/stroke was unrelated to steno-
sis severity (Table 2). In ECST, the highest risk (9.5%)
was observed in patients with moderate stenoses. The
lowest operative risk (3.8%) occurred in those with
90±99% stenoses.12,49,50 One third of strokes/deaths in
NASCETwereapparentuponrecoveryfromanaesthesia
and one third occurred on the first post-operative day.
The rest were distributed over the next 29 days, but
86% had occurred within 7 days of surgery.39 The
same temporal pattern was observed in the ECST. Of
the 122 operative strokes or deaths, 85 (70%) were
evident by the first post-operative day, and 115 (94%)
by the end of the first week (unpublished data).
Factors predictive of increased operative risk in the
ECST14,50 included; (i) female gender (10.4% vs 5.8%,
p 0.0001, hazard ratio 2.05), (ii) peripheral vascular
disease (12.0% vs 6.1%, p5 0.0001, hazard ratio
2.48); (iii) systolic blood pressure (5120 mmHg
3.4%; 121±159 6.5%; 160±180 7.7%; 4180 13.0%;
p 0.04, hazard ratio 2.21), and the nature of the
presenting cerebrovascular event (retinal events
only 3.2%; hemispheric stroke 6.3%, hemispheric
TIA only 9.1%; p5 0.006). All of these factors
remained statistically significant after correction for
other baseline clinical characteristics in a multiple
regression analysis.50 Only 1/147 surgeons undertak-
ing CEA in ECST had an operative risk outwith the
upper 95th confidence interval (95% CI 2.0±8.0%).
However, once the data were corrected for case mix,
this excess risk disappeared.13
Factors predictive of a significantly higher opera-
tive risk in NASCET39 included: (i) hemispheric as
opposed to retinal events (6.3% vs 2.7%, hazard
ratio 2.3), (ii) left vs right CEA (6.7% vs 3.0%, hazard
ratio 2.3), (iii) contralateral occlusion (9.4% vs 4.4%,
hazard ratio 2.2), (iv) ipsilateral CT/MR infarct
(6.3% vs 3.5%, hazard ratio 1.8), and (v) irregular
as opposed to smooth plaque (5.5% vs 3.7%, hazard
ratio 1.5). NASCET observed no association between
age and operative risk (565 years 7.9%, 65±74
years 5.5%, 475 years 5.2%).48 There was a trend
towards increasing risk with age in ECST (555 years
5.6%, 55±65 6.4%, 465 8.7%), but this was not stat-
istically significant (p 0.16), but the operative risk
was lowest (4.4%) in patients aged475 years.
NASCET noted that CEA patients taking aspirin
doses of 5650 mg daily were significantly more likely
to suffer a peri-operative stroke.6 However, a large
randomised trial involving 2849 patients thereafter
showed the converse to be true.52 The available evi-
dence suggests that low dose aspirin (75±300 mg) is
effective in reducing early cardiovascular morbidity/
mortality, whilst avoiding the adverse side effects
associated with higher dose therapy. This dose range
was used in virtually all patients in the ECST.
It is often difficult for a surgeon to gauge how his/
her operative risk actually influences the long-term
benefit of CEA. Table 3 presents a reanalysis of the
ECST data in patients with either a 70±99% or an
80±99% stenosis according to the initial risk. Thus for
a unit with a 2% operative risk when operating upon
patients with a 70±99% stenosis, the relative risk
reduction is 73%, 112 ipsilateral strokes will be pre-
vented per 1000 CEAs and only 9 CEAs are required
to prevent one ipsilateral stroke. If the operative risk
increases to 10% (as in the recent CAVATAS study53),
the relative risk reduction at three years falls to 21% and
32 CEAs are now necessary to prevent one stroke. ECST
has suggested that CEA should be reserved for patients
with 80±99% stenoses.12 Table 3 suggests that such a
policy would greatly increase the overall effectiveness
of the procedure in units with a higher operative risk.
Even if a surgeon had a 10% operative risk, the relative
risk reduction at three years would still be 42%.
Peri-operative medical complications
Ten percent of CEA patients in NASCET suffered a
medical complication in the peri-operative period as
compared with 3.4% of medical patients in the first
Table 2. Peri-operative surgical risk.
ECST NASCET
530%
(n 138)
30±69%
(n 913)
70±99%
(n 750)
30±69%
(n 1087)
70±99%
(n 328)
Operative mortality 1.5% 1.1% 0.9% 1.2% 0.6%
Death /ÿ disabling stroke 2.3% 3.8% 3.7% 2.8% 2.1%
Death /ÿ any stroke 4.6% 7.9% 7.5% 6.7% 5.8%
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30 days after randomisation.38 The commonest were
cardiovascular (CEA 8.1%, medical 1.2%) and
respiratory (CEA 0.8%, medical 0.5%). However,
70% of medical morbidity in CEA patients were
classed as mild, while 27% were moderately severe.
Only 0.3% (5/1415) of CEA patients suffered a major
complication (all myocardial infarction) and no surgi-
cal patient suffered a pulmonary embolus. In ECST,
there were four patients (0.2%) with myocardial
infarction within 30 days of surgery, and two patients
(0.1%) with pulmonary embolism.50
Peri-operative wound and cranial nerve morbidity
One hundred and thirty-two surgical patients in
NASCET (9.3%) suffered a wound complication
(haematoma, infection etc.), but in only 0.3% of
patients was this considered severe.39 Cranial nerve
injuries were documented in 8.6%. Almost all were
classified as mild with full recovery within 30 days.
None suffered a major cranial nerve injury. The com-
monest nerves to be injured were the hypoglossal
(3.7%), vagus (2.5%) and mandibular branch of the
facial nerve (2.2%). No NASCET patient suffered
glossopharyngeal nerve palsy, reflecting the exclusion
of patients with high carotid disease from the trial.19
In ECST, 111 patients (6.4%) suffered a cranial nerve
palsy, 53 patients (3.1%) had a neck haematoma
requiring re-operation, and four patients developed a
significant wound infection.50 Of the patients with
cranial nerve injury, symptoms had resolved by the
time of hospital discharge in 37, and in only 9 cases
were the symptoms permanent (unpublished data).
Causes of late death and stroke
The principal causes of late death within the trials
were myocardial infarction, cancer then stroke.4,6,7 In
NASCET, there were 1039 strokes (ischaemic
(n 1021), haemorrhagic (n 17), subarachnoid
haemorrhage (n 1)) in 749 (26% of 2885) patients
during follow-up.41 Of the 1021 ischaemic strokes,
112 (10.8%) were classed as cardio-embolic, 211
(20.3%) were lacunar, while 698 (67.2%) were consid-
ered large vessel in origin. Cardioembolic strokes
were responsible for the highest proportion of late
disabling strokes. Lacunar strokes were the least
disabling. In ECST, there were 728 strokes in 555
patients, 317 patients had a disabling or fatal stroke,
and there were a total of 820 deaths during follow-up
(unpublished data).
Secondary Analyses
NASCET has published several papers reporting the
effect of CEA, usually in the 70±99% stenosis patients,
stratified according to a single baseline variable, such
as intracranial disease. The ECST has not published
any single variable subgroup analyses, but has used
multiple regression analyses to predict the risks of
stroke on medical treatment and the operative
risk.14,50 The secondary analyses from NASCET have
stimulated debate about who benefits most from CEA,
but must be interpreted with caution until they can be
independently validated. They can be difficult to
interpret because NASCET was not specifically pow-
ered to look at small subgroups. Until the NASCET
observations are assessed in the ECST, it would seem
sensible to use the NASCET secondary analyses only
very cautiously in clinical practice. It is probably more
reasonable to use secondary analyses to determine
who should be fast-tracked for investigation and
surgical treatment, rather than who should not be
considered for surgery.
Table 3. Effect of 30 day operative risk on 3 year rate of ipsilateral stroke in patients with 70±99% or 80±99% ECST stenosis.
Operative
risk (%) 
Surgery Medical
Risk of ipsilateral
CVA/death
at 3 years
Risk of ipsilateral
CVA/death
at 3 years
Absolute risk
reduction
Relative risk
reduction
No of ipsilateral
CVA/death prevented
per 1000 CEAs
No of CEAs to
prevent 1 ipsilateral
CVA/death
70±99% 80±99% 70±99% 80±99% 70±99% 80±99% 70±99% 80±99% 70±99% 80±99% 70±99% 80±99%
0 2.2 2.0 15.3 20.8 13.1 18.8 86 90 132 188 8 5
2 4.2 4.0 15.3 20.8 11.1 16.8 73 81 112 168 9 6
4 6.2 6.0 15.3 20.8 9.1 14.8 60 71 92 148 11 7
6 8.2 8.0 15.3 20.8 7.1 12.8 47 61 72 128 14 8
8 10.2 10.0 15.3 20.8 5.1 10.8 34 52 52 108 19 9
10 12.2 12.0 15.3 20.8 3.1 8.8 21 42 32 88 32 11
Operative risk any stroke or death within 30 days after CEA, 70±99%patients undergoing CEA with a 70±99% ECST stenosis,
80±99%patients undergoing CEA with an 80±99% ECST stenosis.
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Do elderly patients benefit from carotid surgery?
There has been a tendency to avoid CEA in elderly
patients because it is perceived that a higher operative
risk may nullify any long-term benefit. NASCET
found that the long-term benefit of CEA increased
significantly in older patients, without increasing the
operative risk.54 Table 4 presents the two-year risk of
ipsilateral stroke relative to age and degree of stenosis.
Patients aged 475 years consistently derived a better
outcome following CEA, particularly in those with
severe disease. This secondary analysis therefore sug-
gests that biological (as opposed to chronological age)
should be the basis for referral. As was observed in an
accompanying editorial,55 the average life expectancy
of an 85-year-old living in the U.S.A. is six years!
Exactly the same trend towards increasing benefit
from surgery with age was observed in the ECST, and
also when the data from both trials were combined.55
Do patients with subocclusion require urgent
endarterectomy?
There has been much controversy regarding the sig-
nificance of the `` string sign''. NASCET analysed the
30-day and 1-year risks of ipsilateral stroke relative to
stenosis severity and whether or not the `` string sign''
was present (Table 5). Near occlusion with string sign
was defined as a 95±99% stenosis with underfilling/
non-visualisation or collapse of the distal ICA. Near
occlusion with no string implied that the distal ICA
opened into a normal calibre vessel. The one-year risk
of ipsilateral stroke in medically treated patients
increased from 12.8% (70±79% stenosis) to 18.5%
(80±89% stenosis), peaking at 35.1% for 90±94% ste-
noses.34 The one-year risk fell to 18.3% in the presence
of near occlusion and no string sign. The 1-year risk
was lowest in those with angiographic evidence of a
string sign (11%).
When compared with the surgical group (Table 5),
two observations emerge. First, the patient with near
occlusion (with or without the string sign) does not
appear to have an increased risk of stroke within the
next 30 days (medical risk 0.0%, surgical risk
6.7%). Second, the ARR in ipsilateral stroke at 1 year
for those with near occlusion and a string sign was
only 4.4%. This is significantly less than for any other
sub-group and equates to 23 CEAs being necessary to
prevent one ipsilateral stroke. This compares with
four CEAs in those with 90±94% stenoses.
Support also comes from the ECST who used objec-
tive data to measure the degree of post-stenotic
narrowing.15 Post-stenotic narrowing was defined as
an ICA/CCA ratio5 0.42, which represented two
standard deviations below the mean of ICA and CCA
diameters in 2966 carotid arteries with 0±49% stenoses.
Post-stenotic narrowing was not observed until the
stenosis exceeded 70% and was evident in 18% of
patients with 80±99% stenoses.15 The 5-year risk of
stroke in patients with no distal narrowing was
22 and 32% for 80±89% and 90±99% stenoses respec-
tively. This contrasted with an 8% 5-year risk in those
with post-stenotic narrowing.
These data suggest that patients with sub-occlusion
and the string sign do not require expedited surgery.
There is time for more discriminating investigation
and risk profiling. In the past, suspicion of a string
sign with trickle flow on Duplex has prompted formal
angiography with its attendant risks. Because the
stroke risk appears to be low in patients with the string
sign, it might now be reasonable to consider a more
conservative approach in patients (especially female)
presenting with a single ischaemic event (especially
amaurosis fugax). Patients with recurring ipsilateral
events should undergo contrast angiography.
Table 5. 30 day and 1 year risk of ipsilateral stroke relative to degree of stenosis and presence of string sign.
Degree of stenosis
(/ÿ string)
Surgical risk (%) Medical risk (%) ARR (%) RRR (%) NNT CVA prevented
per 1000 CEAs
30 days 12 months 30 days 12 months
70±79% 3.9 4.6 1.4 12.8  8.2 64 12 83
80±89% 6.3 8.7 6.4 18.5  9.8 53 10 100
90±94% 8.7 8.7 4.6 35.1  26.4 75 4 250
95±99%no string 6.1 9.1 2.3 18.3  9.2 50 11 91
95±99% string sign 6.7 6.7 0.0 11.1  4.4 40 23 43
Adapted from Morgenstern et al. on behalf of NASCET.34
Table 4. Effect of age on 2 year risk of ipsilateral stroke.
Age
(years)
Degree of stenosis in randomised artery
550% 50±69% 70±99%
ARR (%) NNT ARR (%) NNT ARR (%) NNT
475 7.3 14 17.3 6 28.9 3
65±74 1.1 91 5.3 19 15.1 7
565 1.4 71 ÿ 1.2 n/a 9.7 10
Adapted from Alamowitch et al. on behalf of NASCET.48
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How long should CEA be deferred after
a completed stroke?
In the 1960s, `` emergency'' CEA after acute stroke was
associated with a 60% risk of haemorrhagic transfor-
mation of the infarct.56 Accordingly, not only was CEA
avoided in patients with stroke due to ICA throm-
bosis, but it became customary to defer CEA for
6±8 weeks in all patients, irrespective of severity.
Improvements in case selection, risk factor control
and ITU/HDU facilities have prompted a reappraisal
of this stance.58 In NASCET, 4.9% of medically treated
patients presenting with stroke and a severe ICA
stenosis suffered a recurrent stroke within 30 days of
randomisation.26 NASCET analysed outcomes in
100 randomised stroke patients with severe disease.26
Although patients in whom CEA was deferred for
430 days were more likely to have an abnormal CT,
there was no difference in the mean diameter of the
infarcts and no difference in the peri-operative risk
(530 days 4.8%, 430 days 5.2%). In particular,
the operative risk was not higher in patients with
an infarct on CT scan (530 days 0.0%,
430 days 5.4%). Both surgical groups had a 12%
risk of ipsilateral stroke at 18 months.26
The numbers are relatively small but suggest that
fear of haemorrhagic transformation should not be the
only consideration when planning the timing of CEA
after stroke. Expedited surgery (54 weeks) should be
considered in patients who make a rapid recovery and
who have relatively small infarction volumes on CT.58
Patients under consideration for CEA with larger
infarcts and significant residual neurological disability
should have surgery deferred for 6±8 weeks as before.
Does multiple co-morbidity reduce the
benefit of CEA?
NASCET analysed the two-year risk of ipsilateral
stroke relative to cumulative risk factors including;
age4 70, stroke on presentation, male sex, 80±99%
stenosis, systolic BP4 160 mmHg, diastolic BP4
90 mmHg, ulceration on angiography, a cerebral
event within the preceding 30 days and a history of
congestive cardiac failure, diabetes, current smoking,
claudication, myocardial infarction, hypertension and
hyper-lipidaemia.4 In medically treated patients, the
2-year risk of ipsilateral stroke increased from 17% for
those with 55 factors to 23% in those with 6 factors
and 39% in patients with 7 risk factors. More
important, the number of risk factors had no influence
on outcome following CEA (9% ipsilateral stroke risk
at two years irrespective of concurrent disease). This
data supports the intuitively held view that the
patient with increasing cardiovascular co-morbidity
has a very high risk of stroke if treated medically.
These high-risk patients can be considered for surgery
without otherwise compromising safety. Similar con-
clusions can be drawn from the risk modelling work
in the ECST14 ± the higher the risk of stroke on medical
treatment, the higher the benefit from surgery, with
relatively little correlation between medical risk and
surgical risk. The only proviso in routine clinical prac-
tice is that randomised controlled trials tend to
include relatively healthy patients. NASCET, in par-
ticular, had stringent exclusion criteria relating to
severe comorbidity.
Should CEA be performed outside the
6 month threshold?
To qualify for the trials, patients had to have suffered
an ipsilateral, carotid territory event within the
preceding 6 months. This was somewhat arbitrary,
but since the trials demonstrated that CEA conferred
a significant benefit in this group, the threshold of
6 months has persisted. However, there are some
data to suggest that the 6-month threshold might be
extended in selected patients with very severe dis-
ease6,12 and other risk factors for stroke. Figure 2
shows the annual risk of stroke in medically treated
patients in the ECST. The annual risk never exceeded
6% for patients with a 70±79% stenosis. The risk for
80±89% stenoses was 11% in the first year and 6% in
the second. The highest risk was observed in those
with a 90±99% stenosis (18% first year risk, 14% in
the second). After 2 years, the annual stroke risk
Fig. 2. Annual risk of stroke in ECST patients randomised to best
medical therapy relative to degree of stenosis at the time of ran-
domisation. Reproduced by permission of The Lancet.12
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never exceeded 3% in any stenosis group. However,
the high stroke risk in the second year of follow-up in
patients with 90±99% stenosis does suggest that this
group might still benefit from surgery after the
6 month threshold.
Following publication of the principal results of
NASCET, the investigators suggested that patients with
severe disease who had been randomised to medical
therapy should now be offered CEA. They subse-
quently observed that 25% had already progressed to
carotid occlusion, of whom 31.7% had suffered a
stroke as a consequence.46 Overall, 21% of medical
patients with 70±84% stenoses progressed to occlusion,
increasing to 32% in those with 85±99% stenoses. The
3-year risk of ipsilateral stroke in medically treated
patients who underwent delayed CEA was 7.9%. This
compared with 15.0% in those maintained on BMT.
However, this is, of course, a non-randomised compari-
son, and it is quite possible that the patients who
declined surgery, or who were not offered surgery, were
at higher risk because of more severe comorbidity or
other factors, and that those patients who had surgery
might also have done better had they had BMT only.
On balance, the 6-month threshold should definitely
be retained for patients with 70±79% ECST stenoses.
However, it would now seem reasonable to consider
surgery for up to 12 months after the last event in
selected patients. Depending on the operative risk of
the surgeon, these might include certain patients with
80±99% stenoses (especially 90±99% but excluding
near-occlusion), who exhibit one or more important
risk factors for stroke on BMT (e.g., male sex, ulcerated
plaque, multiple concurrent risk factors, hemispheric
as opposed to retinal symptoms, recurring events and
contralateral occlusion, etc). This should definitely not
be seen as a reason to extend the time threshold in all
patients. Centres with an operative risk 47% should
probably retain the 6-month threshold for all patients.
Do patients with recurrent symptoms require
expedited assessment?
NASCET compared the risk of late stroke33 in
164 patients with severe disease who reported a
history of carotid territory events over a 46 month
period (recurrent group) with 444 who described
onset of symptoms within the preceding 6 months
(recent group). The 2-year risk of ipsilateral stroke
was 18.6% in medically treated `` recent onset''
patients, compared with 7.8% in patients subjected to
CEA (ARR 10.8%, RRR 58%, NNT 9). However,
the 2 year risk of ipsilateral stroke in medically treated
patients with recurrent cerebral events was 41.2%,
compared to 10.8% in the surgical group
(ARR 30.4%, RRR 59%, NNT 3). This analysis
suggests that expedited investigation and CEA is
sensible in patients reporting recurrent symptoms
over a 46 month time period.
Should patients with retinal TIAs still be
offered carotid surgery?
Both trials analysed outcome according to whether the
patient presented with hemispheric symptoms (hemi-
paresis, hemisensory signs, dysphasia, etc) or retinal
events (amaurosis fugax, central retinal artery occlu-
sion). In ECST,14 patients with hemispheric symptoms
were more than twice as likely to suffer a late stroke
than patients with ocular events (odds ratio 2.5
(95%CI 1.1±3.7). In NASCET patients with severe sten-
osis, the 2-year risk of ipsilateral stroke was 16.6% for
retinal events as compared with 43.5% in those
describing hemispheric symptoms.30
These data suggest that patients with severe disease
and hemispheric symptoms should be allocated a high
priority for rapid investigation and management.
NASCET continues to recommend CEA for patients
with amaurosis fugax.30 Centres with a high operative
risk (7%) might, however, favour medical therapy
(especially in female patients) in those with retinal
symptoms in association with a 70±79% stenosis. On
the other hand, the operative risk in patients with
retinal events only is certainly lower than that in
patients with hemispheric events.59
Do TIA patients with infarcts on CT scan have
a worse long-term prognosis?
NASCET hypothesised that patients presenting with
TIA, 70±99% stenoses and ipsilateral infarction on
CT scan might have a worse prognosis compared
with similar patients with normal CT scans.29 Of the
114 TIA patients with severe disease randomised to
medical therapy, 50 (28%) had CT evidence of ipsi-
lateral infarction. TIA patients with CT evidence of
infarction were significantly more likely to be older
and have more risk factors for stroke (hypertension,
ulcerated plaques, recent symptoms) than TIA
patients with no infarction. Univariate analysis indi-
cated that the presence of infarction doubled the risk
of ipsilateral stroke over a 16-month period. However,
once a multi-variate analysis corrected for other vari-
ables, the excess risk disappeared. Similar conclusions
can be drawn from the risk modelling in the medical
treatment group in the ECST.14
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Does the status of the contralateral ICA
influence outcome?
NASCET examined the risk of ipsilateral stroke (i.e.,
ipsilateral to the treated stenosis, not the non-operated
side) relative to the degree of disease in the contra-
lateral ICA (Table 6).32 The 30-day risk of stroke/death
after CEA was significantly higher in patients with
a severe symptomatic stenosis and contralateral occlu-
sion (14.3%) as compared to patients with contralat-
eral severe (4%) or mild/moderate stenoses (5.1%).
The higher operative risk in patients with contralateral
occlusion was also found in the ECST, and is highly
consistent across published surgical case-series.59
However, despite the higher operative risk, CEA still
conferred a highly significant reduction in the 2-year
risk of ipsilateral stroke in NASCET patients with
severe carotid stenosis and contralateral carotid occlu-
sion (ARR 47.3%, RRR 68%, NNT 2). Patients
with symptomatic severe disease and contralateral
occlusion should therefore be allocated a high priority
for expedited investigation and CEA. They should
also be warned that surgery carries a higher peri-
operative risk.
Do patients presenting with lacunar stroke
benefit from CEA?
This remains a contentious issue. The concern, on the
part of some stroke physicians and neurologists, is
based on the premise that lacunar infarction follows
occlusion of a deep perforating artery, rather than
thrombo-embolism from the ICA. It is an important
question to answer as up to 40% of hemispheric
strokes or CT ve infarcts in the trials were possibly
or probably lacunar in origin.10,43 NASCET analysed
the type of recurrent stroke during follow-up43 and
observed that patients presenting with lacunar stroke
were three times more likely to suffer another lacunar
stroke during follow-up (9.2% vs 2.9%). ECST noted
a non-significant excess risk of late stroke in non-
operated, non-lacunar as opposed to non-operated
lacunar patients.10 However, ECST concluded that
small numbers (43 lacunar patients with severe
carotid disease) prevented conclusions being made
as to whether CEA was less beneficial.10
NASCET analysed the 3-year risk of ipsilateral
stroke in 1158 patients presenting with stroke.43 These
were classified as non-lacunar (n 665), possibly lacu-
nar (n 283) or probably lacunar (n 210) on the basis
of symptoms/signs or CT findings. Table 7 presents
the outcome in stroke patients who had a 50±99%
ipsilateral stenosis. CEA conferred maximum benefit
in patients with non-lacunar strokes (ARR 15.2%,
RRR 61% NNT 7). CEA had less benefit in those
classed as `` possibly'' or `` probably'' lacunar, but still
achieved an ARR of 9% at 3 years.43 One explanation
for CEA being beneficial in lacunar stroke is that by
improving inflow, the subsequent risk of thrombotic
occlusion in the diseased perforating arteries is
reduced. It would have been interesting, therefore, to
see the effect of surgery in patients with lacunar stroke
in NASCET patients with 70±99% stenosis; the group
in which haemodynamic factors would be most likely
to be important. It is unclear why, in contrast to all
their previous papers, NASCET did not stratify their
findings by degree of stenosis in this paper.
The currently available evidence suggests that
patients with cortical stroke should be accorded
a high priority for investigation and surgery. How-
ever, it was still appropriate to offer CEA to patients
with lacunar stroke and a severe stenosis. Centres
with a high operative risk should probably not oper-
ate on patients with lacunar stroke with a moderate
stenosis (50±69% NASCET, 70±79% ECST).
Should CEA be avoided in patients with
tandem intracranial disease?
As with increasing age and multiple co-morbidity,
there is a perception that the presence of tandem intra-
cranial disease (ICD) is a relative contra-indication to
CEA. NASCET analysed 2885 carotid angiograms
and defined ICD as being mild (wall irregularities,
Table 6. Effect of contralateral disease on 2 year risk of stroke
ipsilateral to the operated or medically treated severe carotid
stenosis.
Status of
contralateral ICA
2 year ipsilateral stroke ARR
(%)
RRR
(%)
NNT
Medical
(n 331)
Surgical
(n 328)
570% stenosis (n 559) 26.2 8.3 17.9 68 6
70±99% stenosis (n 57) 29.3 9.3 20.0 68 5
Occlusion (n 43) 69.4 22.1 47.3 68 2
Adapted from Gasecki et al. on behalf of NASCET.32
Table 7. 3 year risk of ipsilateral stroke in patients presenting with
a stroke and 50±99% stenosis: effect of stroke subtype on late
risk.
Type of stroke at
presentation
3 year ipsilateral stroke risk ARR
(%)
RRR
(%)
NNT
Medical
(%)
Surgical
(%)
Non-lacunar 24.9 9.7 15.2 61 7
Possibly lacunar 16.1 7.6 8.5 53 12
Probably lacunar 25.5 16.5 9.0 35 11
Adapted from Inzitari et al. on behalf of NASCET.43
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no stenosis), moderate (550% stenosis) or severe
(50±99% or occlusion) in the infra-clinoid ICA, the
supra-clinoid ICA and the anterior cerebral/middle
cerebral arteries.37 Overall, 67% had no ICD. Intra-
cranial disease was mild in 27%, moderate in 6% and
severe in 0.5%. Factors associated with an increased
incidence of ICD included black patients, ulcerated
plaques, severe extracranial disease and a history of
smoking, hypertension, diabetes, claudication and
ischaemic heart disease.
All subgroups of ICD severity were combined and
outcomes compared with patients with no ICD. The
presence of tandem ICD did not increase the operative
risk following CEA (6.1% vs 6.7%). However, the pres-
ence of ICD conferred an incrementally greater risk of
ipsilateral stroke at three years in medically treated
patients, irrespective of the degree of extracranial
disease (Table 8). The highest risk was observed in
medically treated patients with ICD and an 85±99%
stenosis in whom CEA conferred a 37.1% ARR. Note
that the presence of ICD had no influence on late
stroke risk in surgically treated patients.37
There is currently no evidence that tandem disease
confers increased risk. However, patients with severe
distal ICA disease were probably not randomised in
the trials. Accordingly, if Duplex ultrasound or MRA
does not show evidence of significant abnormalities in
the distal waveform or anatomy, there is no evidence
that routine angiographic visualisation of the intra-
cranial circulation will alter either the early or late
risk in surgical patients.
Should CEA be avoided in patients with
intracranial aneurysm?
It has been speculated that untreated intra-cranial
aneurysms (ICAN) contribute towards an increased
risk of peri-operative and late stroke (presumably
haemorrhagic) and that they are a relative contra-
indication to surgery. NASCET observed that 90/
2885 patients (3.1%) had 99 intracranial aneurysms.45
The majority (83%) were 55 mm. The incidence of
ICAN 410 mm (i.e., considered for neurosurgical
intervention) was 0.3%. The available evidence sug-
gests that ICAN does not influence outcome. The
5-year risk of ipsilateral stroke was 10% in CEA
patients with a non-repaired ICAN as compared to
14.8% in those with no aneurysm. This compares
with a 5-year risk of ipsilateral stroke of 22.7% in
medically treated patients with a non-repaired ICAN
vs 22.5% in those with no aneurysm. The available
evidence suggests that small non-repaired intracranial
aneurysms do not confer an increased early or late risk
of stroke after CEA.
Does knowledge of intracranial collaterals
influence outcome after CEA?
NASCET correlated stroke risk with recruitment of
intracranial collaterals.40 Recruitment of collaterals
was defined as angiographic evidence of flow through
the ipsilateral anterior cerebral, posterior cerebral or
ophthalmic arteries towards the symptomatic ICA. Of
the 2885 patients, 280 (9.7%) had evidence of collateral
recruitment. The commonest pattern was reversed
flow in the ipsilateral anterior cerebral (70%), 9%
recruited via the posterior-communicating artery,
while 20% had multiple pathways. Only five (0.2%)
had retrograde flow in the ophthalmic artery.40
Collateralisation was present in 0.5% with an ICA
stenosis 550%, 3% in patients with a 50±69% stenosis,
25% in those with a 70±84% stenosis and 43% in those
with 85±99% stenoses. The highest prevalence was
observed in those with near occlusion and distal ICA
collapse (64%).
Table 9 details the 2-year risk of ipsilateral stroke
relative to mode of treatment, degree of stenosis and
the presence or absence of collateralisation. With the
exception of patients with near occlusion and distal
ICA collapse, the absence of intracranial collaterals
Table 8. Effect of intracranial disease on the 3 year risk of
ipsilateral stroke. 
Stenosis
degree
Intracranial
disease
Medical
risk (%)
Surgical
risk (%)
ARR
(%)
RRR
(%)
NNT CVA/
1000CEA
550% No 13.8 12.5 1.3 9 77 13
Yes 18.0 13.4 4.6 26 22 45
50±69% No 14.7 10.5 4.2 29 24 42
Yes 19.4 11.8 7.6 39 13 77
70±84% No 23.5 10.1 13.4 57 7 143
Yes 28.8 6.1 22.7 79 4 250
85±99% No 25.3 10.0 15.3 60 7 143
Yes 45.7 8.6 37.1 82 3 333
Adapted from Kappelle et al. on behalf of NASCET.37
Table 9. Influence of intracranial collateral recruitment on 2 year
risk of ipsilateral stroke. 
Stenosis
degree
Intracranial
collaterals
Surgical
risk (%)
Medical
risk (%)
ARR
(%)
RRR
(%)
NNT
70±84% None 7.1 25.4 18.3 72 5
70±84% Yes 3.8 8.0 4.2 53 24
85±99% None 12.3 43.7 31.4 72 3
85±99% Yes 2.7 16.4 13.7 84 7
Distal ICA
collapse
None 10.4 5.3 ÿ5.1 n/a n/a
Distal ICA
collapse
Yes 11.1 10.9 ÿ0.2 n/a n/a
 Adapted from Henderson et al. on behalf of NASCET.40
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incrementally increased the two-year risk of ipsilateral
stroke in medically treated patients with increasingly
severe extracranial disease. Conversely, the presence
of intracranial collaterals had no effect on the late
stroke risk in surgical patients. Note, however, that
the risk of late stroke fell dramatically in those with
near occlusion and no collateralisation and that
surgery conferred no apparent benefit.40
Knowledge about recruitment of intracranial
collateral pathways does not influence early or late
outcome after CEA.
Is plaque surface irregularity associated with
an increased risk of stroke?
There has been much debate whether plaque irregu-
larity/ulceration increases the risk of stroke in
medically treated patients. NASCET observed no asso-
ciation between degree of carotid stenosis and plaque
ulceration, although only patients with 70±99%
stenosis were reported. However, the presence of
ulceration was associated with a significantly higher
incidence of contralateral severe disease.22 ECST
found that the prevalence of plaque irregularity
increased from 10% in patients with a stenosis 510%,
to 70% in those with 90±99% stenoses. The proportion
of patients with adherent thrombus increased from
12% in patients with520% stenoses to 45% in patients
with 90±99% stenoses.16 The NASCET-ACAS plaque
project observed that intra-plaque haemorrhage was
not associated with either aspirin usage or neovascu-
larity, but was more prevalent in severely stenosed
plaques.21
Both trials found that the presence of plaque
`` irregularity'' or `` ulceration'' increased the risk of
late, ipsilateral stroke on medical treatment. In the
ECST, the 2-year risk of ipsilateral stroke in medically
treated patients with an irregular 80±89% stenosis was
26% vs 15% for smooth lesions. Similar statistics for
patients with irregular 90±99% stenoses were 31%
vs 20% respectively.16 Table 10 presents parallel data
from NASCET. As can be seen, plaque irregularity
increased the 2-year risk of ipsilateral stroke relative
to the degree of stenosis. The highest stroke risk was
observed in patients with 95% stenoses and ulceration
(73.2% at 2 years) in whom CEA conferred a 54% ARR
(RRR 74%, NNT 2). Plaque irregularity had no
effect on outcome in surgically treated patients. The
ECST have also shown that patients with evidence of
plaque irregularity were significantly more likely to
have suffered a myocardial infarction in the past and
were significantly more likely to suffer an MI or
sudden cardiac death in the future.17 This observation
supports the prevailing view that systemic factors
may be important in mediating acute cardiovascular
events.
However, these results relate to angiographic ulcer-
ation and not directly to plaque histology. In the ECST,
1066 angiograms were considered `` irregular'', but
the operating surgeon only scored 779 of these (73%)
as being macroscopically ulcerated.16 Conversely,
605 plaques were considered smooth on angiography,
but 252 (42%) were later classed as macroscopically
ulcerated by the surgeon. In NASCET, the sensi-
tivity for diagnosing an ulcerated plaque on angiog-
raphy was 46%, with a specificity of 74%.24 However,
in practical terms, plaque irregularity on angiography
(and probably also on Duplex) confers an increased
stroke risk on medical treatment (hence the need
for expedited investigation), and should also alert
the investigating clinician to screen for potential
ischaemic heart disease.
What is the risk of stroke in the asymptomatic
contralateral hemisphere?
In the ECST, 2295 asymptomatic contralateral carotid
arteries were followed up for a mean of 4.5 years.9 Of
the 69 late ipsilateral strokes observed, only 13 (19%)
occurred in the territory supplied by a 70±99% sten-
osis. Fifty-four (78%) were ipsilateral to mild or mod-
erate ICA stenoses, while two (3%) were ipsilateral
to an ICA occlusion. The annual risk of ischaemic
stroke distal to an asymptomatic 70±99% stenosis
was approximately 2%.9 Thus, an asymptomatic con-
tralateral stenosis in a recently symptomatic patient
does not appear to be associated with a higher risk of
stroke than asymptomatic stenoses in truly asymp-
tomatic patients.
Up to 24% of `` asymptomatic contralateral hemi-
spheres'' in NASCET had CT evidence of ischaemic
infarction.44 NASCET analysed the 5-year stroke risk
in the asymptomatic hemisphere contralateral to that
randomised in the trial, relative to the degree of
Table 10. 2 year risk of ipsilateral stroke in patients with severe
carotid disease and plaque ulceration. 
Stenosis
(%)
Plaque
ulcer
Surgical
risk (%)
Medical
risk (%)
ARR
(%)
RRR
(%)
NNT
75 No 10.6 21.2 10.6 50 9
75 Yes 6.9 26.3 19.4 74 5
85 No 10.6 21.3 10.7 50 9
85 Yes 11.5 43.9 32.4 74 3
95 No 10.7 21.3 10.6 50 9
95 Yes 19.2 73.2 54.0 74 2
 Adapted from Eliasziw et al. on behalf of NASCET.22
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stenosis. The 5-year risk increased from 7.8% (450%
stenosis) to 12.9% (50±59%), 14.8% (60±74%) and
18.5% (75±94%). Interestingly, the 5-year risk fell to
14.7% in those with near occlusion. The lowest
5-year risk (9.4%) was observed in patients known to
have carotid occlusion from the outset. In NASCET,
approximately 50% of all strokes in the territory of an
asymptomatic, contralateral 60±99% ICA stenosis
were not considered to be of large artery origin.41
Are there any models that predict the
late stroke risk?
The large trials have shown that CEA confers a major
reduction in the risk of stroke as compared with BMT
alone in patients with a 70±99% stenosis. However, it
is also clear that the majority (approximately 75%) of
patients with 70±99% stenosis will not suffer a stroke
during follow-up with BMT alone. There has therefore
been interest in identifying which individuals are at
highest risk of stroke, and most likely therefore to
benefit from CEA.
In order to derive a model that could be tested in the
70±99% stenosis patients, the ECST undertook a multi-
variate analysis in the 857 medically treated patients
with a 0±69% stenosis to identify factors significantly
predictive of late ipsilateral stroke.13 Three factors
(Table 11) were identified; (i) hemispheric as opposed
to ocular events (OR 2.5 (95%CI 1.1±3.7)), (ii) irregular
vs smooth plaques (OR 2.1 (95%CI 1.2±3.6)) and
(iii) events in the preceding 2 months (OR 1.8 (95%CI
1.02±3.2)). Each was assigned a score of one.
Thereafter an allowance was made for increasing
degrees of stenosis above 70% (70±79% scored 0, 80±
89% scored 1 point and 90±99% scored 2). Thus the
maximum score for predicting late stroke risk in med-
ically treated patients was 5. Next, a correction was
made to account for the operative risk. A similar
multivariate analysis identified factors predictive of
an increased risk of operative stroke in 1203 surgical
patients with 0±69% stenosis. Three were identified
(Table 11); (i) female sex (OR 2.05 (95%CI 1.3±3.2)),
(ii) history of claudication (OR 2.5 (95%CI 1.4±4.1))
and (iii) systolic blood pressure 4180 mmHg (OR 2.2
(95% CI 1.3±3.8)). Each was assigned a score of 0.5 and
the `` surgical`` total subtracted from the medical score.
The investigators thereafter applied this scoring
system to the medically and surgically treated ECST
patients with 70±99% stenoses. They demonstrated
that patients with a score of 3.5 had a 12% 5 year
risk of ipsilateral stroke if treated medically (Table 12)
as opposed to 11% in the surgical group (ARR 1% over
5 years, RRR 8.3%, NNT 100). However, medically
treated patients with a score 4 had a 40% 5-year risk
of stroke as compared with 7% for the surgical group
(ARR 33%, RRR 83%, NNT 3). If this scoring sys-
tem were applied to current surgical practice (i.e., only
operate on patients with a score 4), fewer than 20%
of patients currently considered for CEA would
require surgery.13
This is the first attempt to develop an evidence-
based scoring system to target CEA towards the
highest risk patients. This method is currently being
tested on the NASCET database to see if it can be
applied to other populations of patients.
Generalisability of the Trial Results
Strictly speaking, the ECST and NASCET results
apply only to those centres and surgeons who partici-
pated in the studies. However, it is increasingly
assumed that the trial results are generalisable to
routine clinical practice. However, less than 0.5% of
Table 11. ECSTscoring system for predicting risk of late ipsilateral
stroke. 
Predictive risk factor Odds ratio 95%CI Score
Medical risk y
Cerebral versus ocular 2.5 1.1±3.7 1
Plaque surface irregularity 2.1 1.2±3.6 1
Events in preceding 2 months 1.8 1.02±3.2 1
Degree of ICA stenosis 1.3 1.1±1.4 0 for 70±79%
1 for 80±89%
2 for 90±99%
Surgical risk y
(Subtract)
Female 2.05 1.3±3.2 0.5
Claudication 2.5 1.5±4.1 0.5
Systolic BP4180 mmHg 2.2 1.3±3.8 0.5
Adapted from Rothwell et al. on behalf of ECST.14
yThus a female patient with two hemispheric TIAs within the pre-
ceding 2 months and who had a 90±99% irregular stenosis on
angiography and a past history of claudication would score 5 on
the medical risk scale but would have 1.0 deducted (the surgical risk
scale) for being female and having a history of claudication. The
overall score would be 4.
Table 12. 5 year risk of stroke using the ECST prognostic scoring
system. 
Risk score Actuarial predicted 5 year risk y
Surgery
(%)
Medical
(%)
ARR
(%)
RRR
(%)
NNT
0±3.5 11 12 1 8.3 100
4±5 7 40 33 82.5 3
Adapted from Rothwell et al. on behalf of ECST.14
yThus the patient example described in Table 11 scored 4 and would
be predicted to have a 40% risk of stroke in the next 5 years.
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patients undergoing CEA in North America between
1988±1989 were actually randomised into NASCET.20
Second, it is argued that only the `` best'' surgeons
participated in the studies and their results may not
reflect actual practice. Although data are unavailable
for the ECST and NASCET, ACAS rejected 40% of
surgeon applicants following review of their `` track
record''.60 That surgical practice can vary has been
evident for decades. While NASCET was underway,
Hsai simultaneously audited mortality following
CEA in Medicare beneficiaries.61 The operative mor-
tality was five times higher than in NASCET (3.0%
vs 0.6%). When repeated in 1998, mortality was still
two times higher.62 Non-NASCET centres currently
perform 94% of all CEAs in the U.S.A. with a mor-
tality rate significantly higher than that observed in
NASCET centres.63,64 Evidence for worse outcomes
than the ECST in Europe include the 9.9% death/
stroke rate in the CAVATAS trial.53 The evidence
indicates that patient and surgeon selection can
significantly influence the effectiveness of CEA, and
that clinicians must take this into account when apply-
ing the results of the trials to their own practice.
Accordingly, the conclusions regarding clinical prac-
tice given in this review will not apply to centres
whose operative risk is outside that reported in the
trials.
Conclusions
 The simple assumption that ALL patients with a
symptomatic stenosis >70% will benefit from CEA
is untenable. Approximately 75% will not have a
stroke if treated medically.
 Development of local protocols for patient selection
(or exclusion) should involve surgeons and physi-
cians and should take local operative risk into
account.
 There is anecdotal evidence that the investigation
and referral of patients for CEA is taking too long.
The ECST and NASCET have identified subgroups
who should have expedited investigation and
surgery (male sex, 90±99% stenosis, hemispheric
symptoms, recurrent events for 46 months, contra-
lateral occlusion, multiple risk factors).
 Surgeons must quote their own results and be
aware that a high operative risk reduces long-term
benefit. Accordingly, in those centres with higher
operative death/stroke rate, certain `` lower risk''
patients should probably be considered for best
medical therapy alone.
 The ECST and NASCET have shown that the
ubiquitous string sign is not associated with a high
risk of stroke, and emergency endarterectomy is
unnecessary.
 It is hoped that pooling of the ECST and NASCET
databases will enable more definitive guidelines to be
developed regarding who benefits most from CEA.
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